Innate Pharma SA, in collaboration with Sanofi, shared updated efficacy and safety results from a Phase 1/2 dose-escalation study of SAR443579 / IPH6101 ( venetoclax ), an investigational Natural Killer Cell Engager (NKCE). The results were presented at the American Society of Hematology 2023 Annual Meeting in San Diego, California.

SAR443579 is a CD123 targeting NKp46/CD16-based NKCE being tested as monotherapy for blood cancers that lack sufficient treatment options, specifically relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). The therapy has received FDA Fast Track Designation for treating AML.

As of July 5, 2023, the study analyzed 43 patients who had received a median of 2 lines of prior treatments. Many had also been exposed to venetoclax, a therapy for chronic lymphocytic leukemia. At the highest dose level utilized in the study (1000 μg/kg QW), about one-third of AML patients achieved complete remission (CR), with a well-tolerated safety profile observed up to 6000 μg/kg QW.

These emerging results show the durable clinical efficacy and favorable safety of SAR443579, offering hope for the continuation of development in blood cancers. Sonia Quaratino, Chief Medical Officer of Innate Pharma, expressed enthusiasm for advancing the development of multi-specific NK Cell Engagers leveraging Innate’s ANKET platform®. Peter Adamson from Sanofi reiterated this sentiment, emphasizing the potential importance of SAR443579 for AML patients with limited treatment options.

The ANKET® platform is Innate’s proprietary technology for developing a new class of molecules to induce synthetic immunity against cancer. Innate’s research collaboration and license agreement with Sanofi apply this technology to develop innovative, multi-specific antibody formats that engage NK cells through the NKp46 receptor.

Source link: http://www.businesswire.com/news/home/20231210199351/en/Innate-Pharma-Shares-Efficacy-and-Safety-Phase-1-2-Results-of-NK-Cell-Engager-SAR443579-IPH6101-Developed-by-Sanofi-at-ASH-2023

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.